Rilpivirine in the light of the genotypic drug resistance data

HIV and AIDS Review

Volumn 12, Issue 4, 2013, Pages 89-92

  Parczewski, Miłosz ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Antiretroviral treatment; Drug resistance mutations; NNRTI; Rilpivirne

Indexed keywords

EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RILPIVIRINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; CLADISTICS; CROSS RESISTANCE; GENETIC VARIABILITY; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; REVIEW; VIRUS LOAD; VIRUS MUTANT; VIRUS MUTATION; VIRUS TRANSMISSION;

EID: 84888000976     PISSN: 17301270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hivar.2013.09.004     Document Type: Review

References (25)

1. N. Ford, J. Lee, I. Andrieux-Meyer, and A. Calmy Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings HIV/AIDS 3 2011 35 44
2. B.C. Johnson, G.T. Pauly, G. Rai, D. Patel, J.D. Bauman, and H.L. Baker A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants Retrovirology 9 2012 99
3. H. Azijn, I. Tirry, J. Vingerhoets, M.P. de Bethune, G. Kraus, and K. Boven TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1 Antimicrob. Agents Chemother. 54 2010 718 727
4. J.M. Molina, N. Clumeck, K. Redant, L. Rimsky, S. Vanveggel, and M. Stevens Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100,000 copies/ml or less: week 48 phase III analysis AIDS 27 2013 889 897
5. N. Patel, and C.D. Miller New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir HIV/AIDS 4 2012 61 71
6. C.J. Cohen, J.M. Molina, P. Cahn, B. Clotet, J. Fourie, and B. Grinsztejn Efficacy and safety of rilpivirine (TMC278) vs. efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials J. Acquir. Immune Defic. Syndr. 60 2012 33 42
7. M. Bonafede, T. Juday, G. Lenhart, K. Pan, T. Hebden, and T. Correll Cost-effectiveness of efavirenz vs rilpivirine in HIV patients initiating first-line combination antiretroviral therapy J. Med. Econom. 16 2013 552 559
8. Polish Scientific AIDS Society Principles of Care for the HIV-Infected Patients 2013 Zasady opieki nad osobami zakażonymi HIV 2013 2013 PTN AIDS, Eko-Press Warszawa (in Polish)
9. European AIDS Clinical Society, Guidelines v 6.1, 2011. http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/ EacsGuidelines-v6.1-2edition.pdf.
10. M. Balamane, V. Varghese, G.L. Melikian, W.J. Fessel, D.A. Katzenstein, and R.W. Shafer Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine Antimicrob. Agents Chemother. 56 2012 4522 4530
11. EMEA, EVIPLERA - Summary of Product Characteristics, 2013. Published Online http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/002312/WC500118802.pdf.
12. V.A. Johnson, V. Calvez, H.F. Gunthard, R. Paredes, D. Pillay, and R.W. Shafer Update of the drug resistance mutations in HIV-1: March 2013 Topics Antivir. Med. 21 2013 6 14
13. S. Lambert-Niclot, C. Charpentier, A. Storto, D.B. Fofana, C. Soulie, and S. Fourati Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses J. Antimicrob. Chemother. 68 2013 1237 1242
14. L. Rimsky, V. Van Eygen, A. Hoogstoel, M. Stevens, K. Boven, and G. Picchio 96-week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials Antivir. Ther. 2013 10.3851/IMP2636 [Epub ahead of print]
15. J. Vingerhoets, L. Rimsky, V. Van Eygen, S. Nijs, S. Vanveggel, and K. Boven Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response Antivir. Ther. 18 2013 253 256
16. E.L. Asahchop, M.A. Wainberg, M. Oliveira, H. Xu, B.G. Brenner, and D. Moisi Distinct resistance patterns to etravirine and rilpivirine in viruses containing nonnucleoside reverse transcriptase inhibitor mutations at baseline AIDS 27 2013 879 887
17. L. Rimsky, J. Vingerhoets, V. Van Eygen, J. Eron, B. Clotet, and A. Hoogstoel Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis J. Acquir. Immune Defic. Syndr. 59 2012 39 46
18. K. Singh, B. Marchand, D.K. Rai, B. Sharma, E. Michailidis, and E.M. Ryan Biochemical mechanism of HIV-1 resistance to rilpivirine J. Biol. Chem. 287 2012 38110 38120
19. R. Kulkarni, K. Babaoglu, E.B. Lansdon, L. Rimsky, V. Van Eygen, and G. Picchio The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness J. Acquir. Immune Defic. Syndr. 59 2012 47 54
20. H.T. Xu, S.P. Colby-Germinario, E.L. Asahchop, M. Oliveira, M. McCallum, and S.M. Schader The effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation in defining patterns of resistance to the non-nucleoside reverse transcriptase inhibitors rilpivirine and etravirine Antimicrob. Agents Chemother. 2013
21. H. Crauwels, R.P. van Heeswijk, M. Stevens, A. Buelens, S. Vanveggel, and K. Boven Clinical perspective on drugdrug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine AIDS Rev. 15 2013 87 101
22. C. Reinheimer, H.W. Doerr, and M. Sturmer Prevalence of TMC278 (rilpivirine) associated mutations in the Frankfurt Resistance Database J. Clin. Virol.: Off. Publ. Pan Am. Soc. Clin. Virol. 53 2012 248 250
23. C.J. Cohen, J.M. Molina, I. Cassetti, P. Chetchotisakd, A. Lazzarin, and C. Orkin Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials AIDS 27 2013 939 950
24. L. Anta, J.M. Llibre, E. Poveda, J.L. Blanco, M. Alvarez, and M.J. Perez-Elias Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies AIDS 27 2013 81 85
25. T. Bunupuradah, J. Ananworanich, P. Chetchotisakd, P. Kantipong, S. Jirajariyavej, and S. Sirivichayakul Etravirine and rilpivirine resistance in HIV-1 subtype CRF01-AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens Antivir. Ther. 16 2011 1113 1120